Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2018-08-28 | Dr. Breitfeld was most recently Global Vice President at Quintiles... He has approximately 50 publications in the literature dealing with basic cell and molecular biology, and translational and clinical oncology. |
| 2019-08-28 | He was trained in Pediatric Hematology/Oncology at the Dana-Farber Cancer Institute, was a visiting scientist at the Whitehead Institute at MIT, received his medical degree (MD) from the University of Rochester, and his undergraduate degree (AB in chemistry) from Princeton. |
| 2020-08-28 | Dr. Breitfeld was trained in Pediatric Hematology/Oncology at the Dana-Farber Cancer Institute, was a visiting scientist at the Whitehead Institute at MIT, received his medical degree (MD) from the University of Rochester, and his undergraduate degree (AB in chemistry) from Princeton. |
| 2021-08-30 | He received his medical degree (MD) from the University of Rochester, and his undergraduate degree (AB in chemistry) from Princeton. |
| 2022-08-31 | He was trained in Pediatric Hematology/Oncology at the Dana-Farber Cancer Institute, was a visiting scientist at the Whitehead Institute at MIT, received his medical degree (MD) from the University of Rochester. |
| 2023-08-28 | He was trained in Pediatric Hematology/Oncology at the Dana-Farber Cancer Institute, was a visiting scientist at the Whitehead Institute at MIT, received his medical degree (MD) from the University of Rochester. |
| 2024-08-27 | He received his medical degree (MD) from the University of Rochester, and his undergraduate degree (AB in chemistry) from Princeton. |
Data sourced from SEC filings. Last updated: 2025-07-01